Report Detail
Global Interferon Alpha-2a Biosimilar Market Insights, Forecast to 2025
- RnM2953563 |
- 16 February, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
The global average price of Interferon Alpha-2a Biosimilar is in the decreasing trend, from 186.78 USD/Unit in 2013 to 64.67 USD/Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Interferon Alpha-2a Biosimilar includes ordinary type and long-lasting type, and the proportion of ordinary type in 2017 is about 64%, and the proportion is in increasing trend from 2013 to 2017.
Interferon Alpha-2a Biosimilar is widely used for hepatitis C, hepatitis B and other diseases. The most proportion of Interferon Alpha-2a Biosimilar is used for hepatitis C, and the proportion in 2017 is 46%.
Europe is the largest supplier of Interferon Alpha-2a Biosimilar, with a production market share nearly 70% in 2017.
South America is the largest consumption place, with a consumption market share nearly 26% in 2017. Following South America, Europe is the second largest consumption place with the consumption market share of 22%.
Market competition is not intense. Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Interferon Alpha-2a Biosimilar market is valued at 390 million US$ in 2018 and will reach 150 million US$ by the end of 2025, growing at a CAGR of -11.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Interferon Alpha-2a Biosimilar market based on company, product type, end user and key regions.
This report studies the global market size of Interferon Alpha-2a Biosimilar in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Interferon Alpha-2a Biosimilar in these regions.
This research report categorizes the global Interferon Alpha-2a Biosimilar market by top players/brands, region, type and end user. This report also studies the global Interferon Alpha-2a Biosimilar market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Biosidus
Zydus Cadila
Nanogen
Amega Biotech
Rhein Minapharm Biogenetics
PROBIOMED
3sbio
Market size by Product
Long-lasting Type
Ordinary Type
Market size by End User
Hepatitis C
Hepatitis B
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Interferon Alpha-2a Biosimilar market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Interferon Alpha-2a Biosimilar market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Interferon Alpha-2a Biosimilar companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Interferon Alpha-2a Biosimilar submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Interferon Alpha-2a Biosimilar are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Interferon Alpha-2a Biosimilar market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Interferon Alpha-2a Biosimilar Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Interferon Alpha-2a Biosimilar Market Size Growth Rate by Product
- 1.4.2 Long-lasting Type
- 1.4.3 Ordinary Type
- 1.5 Market by End User
- 1.5.1 Global Interferon Alpha-2a Biosimilar Market Size Growth Rate by End User
- 1.5.2 Hepatitis C
- 1.5.3 Hepatitis B
- 1.5.4 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Interferon Alpha-2a Biosimilar Market Size
- 2.1.1 Global Interferon Alpha-2a Biosimilar Revenue 2014-2025
- 2.1.2 Global Interferon Alpha-2a Biosimilar Sales 2014-2025
- 2.2 Interferon Alpha-2a Biosimilar Growth Rate by Regions
- 2.2.1 Global Interferon Alpha-2a Biosimilar Sales by Regions
- 2.2.2 Global Interferon Alpha-2a Biosimilar Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Interferon Alpha-2a Biosimilar Sales by Manufacturers
- 3.1.1 Interferon Alpha-2a Biosimilar Sales by Manufacturers
- 3.1.2 Interferon Alpha-2a Biosimilar Sales Market Share by Manufacturers
- 3.1.3 Global Interferon Alpha-2a Biosimilar Market Concentration Ratio (CR5 and HHI)
- 3.2 Interferon Alpha-2a Biosimilar Revenue by Manufacturers
- 3.2.1 Interferon Alpha-2a Biosimilar Revenue by Manufacturers (2014-2019)
- 3.2.2 Interferon Alpha-2a Biosimilar Revenue Share by Manufacturers (2014-2019)
- 3.3 Interferon Alpha-2a Biosimilar Price by Manufacturers
- 3.4 Interferon Alpha-2a Biosimilar Manufacturing Base Distribution, Product Types
- 3.4.1 Interferon Alpha-2a Biosimilar Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Interferon Alpha-2a Biosimilar Product Type
- 3.4.3 Date of International Manufacturers Enter into Interferon Alpha-2a Biosimilar Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Interferon Alpha-2a Biosimilar Sales by Product
- 4.2 Global Interferon Alpha-2a Biosimilar Revenue by Product
- 4.3 Interferon Alpha-2a Biosimilar Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Interferon Alpha-2a Biosimilar Breakdown Data by End User
6 North America
- 6.1 North America Interferon Alpha-2a Biosimilar by Countries
- 6.1.1 North America Interferon Alpha-2a Biosimilar Sales by Countries
- 6.1.2 North America Interferon Alpha-2a Biosimilar Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Interferon Alpha-2a Biosimilar by Product
- 6.3 North America Interferon Alpha-2a Biosimilar by End User
7 Europe
- 7.1 Europe Interferon Alpha-2a Biosimilar by Countries
- 7.1.1 Europe Interferon Alpha-2a Biosimilar Sales by Countries
- 7.1.2 Europe Interferon Alpha-2a Biosimilar Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Interferon Alpha-2a Biosimilar by Product
- 7.3 Europe Interferon Alpha-2a Biosimilar by End User
8 Asia Pacific
- 8.1 Asia Pacific Interferon Alpha-2a Biosimilar by Countries
- 8.1.1 Asia Pacific Interferon Alpha-2a Biosimilar Sales by Countries
- 8.1.2 Asia Pacific Interferon Alpha-2a Biosimilar Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Interferon Alpha-2a Biosimilar by Product
- 8.3 Asia Pacific Interferon Alpha-2a Biosimilar by End User
9 Central & South America
- 9.1 Central & South America Interferon Alpha-2a Biosimilar by Countries
- 9.1.1 Central & South America Interferon Alpha-2a Biosimilar Sales by Countries
- 9.1.2 Central & South America Interferon Alpha-2a Biosimilar Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Interferon Alpha-2a Biosimilar by Product
- 9.3 Central & South America Interferon Alpha-2a Biosimilar by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Interferon Alpha-2a Biosimilar by Countries
- 10.1.1 Middle East and Africa Interferon Alpha-2a Biosimilar Sales by Countries
- 10.1.2 Middle East and Africa Interferon Alpha-2a Biosimilar Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Interferon Alpha-2a Biosimilar by Product
- 10.3 Middle East and Africa Interferon Alpha-2a Biosimilar by End User
11 Company Profiles
- 11.1 Roche
- 11.1.1 Roche Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Roche Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Roche Interferon Alpha-2a Biosimilar Products Offered
- 11.1.5 Roche Recent Development
- 11.2 Biosidus
- 11.2.1 Biosidus Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Biosidus Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Biosidus Interferon Alpha-2a Biosimilar Products Offered
- 11.2.5 Biosidus Recent Development
- 11.3 Zydus Cadila
- 11.3.1 Zydus Cadila Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Zydus Cadila Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Zydus Cadila Interferon Alpha-2a Biosimilar Products Offered
- 11.3.5 Zydus Cadila Recent Development
- 11.4 Nanogen
- 11.4.1 Nanogen Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Nanogen Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Nanogen Interferon Alpha-2a Biosimilar Products Offered
- 11.4.5 Nanogen Recent Development
- 11.5 Amega Biotech
- 11.5.1 Amega Biotech Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Amega Biotech Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Amega Biotech Interferon Alpha-2a Biosimilar Products Offered
- 11.5.5 Amega Biotech Recent Development
- 11.6 Rhein Minapharm Biogenetics
- 11.6.1 Rhein Minapharm Biogenetics Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Rhein Minapharm Biogenetics Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Rhein Minapharm Biogenetics Interferon Alpha-2a Biosimilar Products Offered
- 11.6.5 Rhein Minapharm Biogenetics Recent Development
- 11.7 PROBIOMED
- 11.7.1 PROBIOMED Company Details
- 11.7.2 Company Business Overview
- 11.7.3 PROBIOMED Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 PROBIOMED Interferon Alpha-2a Biosimilar Products Offered
- 11.7.5 PROBIOMED Recent Development
- 11.8 3sbio
- 11.8.1 3sbio Company Details
- 11.8.2 Company Business Overview
- 11.8.3 3sbio Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 3sbio Interferon Alpha-2a Biosimilar Products Offered
- 11.8.5 3sbio Recent Development
12 Future Forecast
- 12.1 Interferon Alpha-2a Biosimilar Market Forecast by Regions
- 12.1.1 Global Interferon Alpha-2a Biosimilar Sales Forecast by Regions 2019-2025
- 12.1.2 Global Interferon Alpha-2a Biosimilar Revenue Forecast by Regions 2019-2025
- 12.2 Interferon Alpha-2a Biosimilar Market Forecast by Product
- 12.2.1 Global Interferon Alpha-2a Biosimilar Sales Forecast by Product 2019-2025
- 12.2.2 Global Interferon Alpha-2a Biosimilar Revenue Forecast by Product 2019-2025
- 12.3 Interferon Alpha-2a Biosimilar Market Forecast by End User
- 12.4 North America Interferon Alpha-2a Biosimilar Forecast
- 12.5 Europe Interferon Alpha-2a Biosimilar Forecast
- 12.6 Asia Pacific Interferon Alpha-2a Biosimilar Forecast
- 12.7 Central & South America Interferon Alpha-2a Biosimilar Forecast
- 12.8 Middle East and Africa Interferon Alpha-2a Biosimilar Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Interferon Alpha-2a Biosimilar Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Interferon Alpha-2a Biosimilar . Industry analysis & Market Report on Interferon Alpha-2a Biosimilar is a syndicated market report, published as Global Interferon Alpha-2a Biosimilar Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Interferon Alpha-2a Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
